Body-mass index and metastatic melanoma outcomes – Authors' reply

Jennifer L. McQuade; Carrie R. Daniel; Michael A. Davies

doi:10.1016/S1470-2045(18)30266-3

Body-mass index and metastatic melanoma outcomes – Authors' reply

Jennifer L. McQuade, Carrie R. Daniel, Michael A. Davies

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e227-e228
Journal	The lancet oncology
Volume	19
Issue number	5
DOIs	https://doi.org/10.1016/S1470-2045(18)30266-3
State	Published - May 2018

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(18)30266-3

Cite this

@article{932e11a448054617aa5e60994e2c8448,

title = "Body-mass index and metastatic melanoma outcomes – Authors' reply",

author = "McQuade, {Jennifer L.} and Daniel, {Carrie R.} and Davies, {Michael A.}",

note = "Funding Information: MD reports personal fees from Novartis, grants and personal fees from Roche/Genentech, personal fees from Bristol Myers Squibb, grants and personal fees from Sanofi-Aventis, grants from Astrazeneca, and grants from Merck outside the submitted work. The other authors declare no competing interests.",

year = "2018",

month = may,

doi = "10.1016/S1470-2045(18)30266-3",

language = "English (US)",

volume = "19",

pages = "e227--e228",

journal = "The lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "5",

}

TY - JOUR

T1 - Body-mass index and metastatic melanoma outcomes – Authors' reply

AU - McQuade, Jennifer L.

AU - Daniel, Carrie R.

AU - Davies, Michael A.

N1 - Funding Information: MD reports personal fees from Novartis, grants and personal fees from Roche/Genentech, personal fees from Bristol Myers Squibb, grants and personal fees from Sanofi-Aventis, grants from Astrazeneca, and grants from Merck outside the submitted work. The other authors declare no competing interests.

PY - 2018/5

Y1 - 2018/5

UR - http://www.scopus.com/inward/record.url?scp=85046029477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046029477&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30266-3

DO - 10.1016/S1470-2045(18)30266-3

M3 - Letter

C2 - 29726386

AN - SCOPUS:85046029477

SN - 1470-2045

VL - 19

SP - e227-e228

JO - The lancet oncology

JF - The lancet oncology

IS - 5

ER -

Body-mass index and metastatic melanoma outcomes – Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this